key: cord-0856988-yrcbp2ju
authors: Chew, Michelle S.; Kattainen, Salla; Haase, Nicolai; Buanes, Eirik A.; Kristinsdottir, Linda B.; Hofsø, Kristin; Laake, Jon Henrik; Kvåle, Reidar; Hästbacka, Johanna; Reinikainen, Matti; Bendel, Stepani; Varpula, Tero; Walther, Sten; Perner, Anders; Flaatten, Hans K.; Sigurdsson, Martin I.
title: A descriptive study of the surge response and outcomes of ICU patients with COVID‐19 during first wave in Nordic countries
date: 2021-10-03
journal: Acta Anaesthesiol Scand
DOI: 10.1111/aas.13983
sha: d6e4778e04e784f3d868822ebdfbb3e582415727
doc_id: 856988
cord_uid: yrcbp2ju

BACKGROUND: We sought to provide a description of surge response strategies and characteristics, clinical management and outcomes of patients with severe COVID‐19 in the intensive care unit (ICU) during the first wave of the pandemic in Denmark, Finland, Iceland, Norway and Sweden. METHODS: Representatives from the national ICU registries for each of the five countries provided clinical data and a description of the strategies to allocate ICU resources and increase the ICU capacity during the pandemic. All adult patients admitted to the ICU for COVID‐19 disease during the first wave of COVID‐19 were included. The clinical characteristics, ICU management and outcomes of individual countries were described with descriptive statistics. RESULTS: Most countries more than doubled their ICU capacity during the pandemic. For patients positive for SARS‐CoV‐2, the ratio of requiring ICU admission for COVID‐19 varied substantially (1.6%–6.7%). Apart from age (proportion of patients aged 65 years or over between 29% and 62%), baseline characteristics, chronic comorbidity burden and acute presentations of COVID‐19 disease were similar among the five countries. While utilization of invasive mechanical ventilation was high (59%–85%) in all countries, the proportion of patients receiving renal replacement therapy (7%–26%) and various experimental therapies for COVID‐19 disease varied substantially (e.g. use of hydroxychloroquine 0%–85%). Crude ICU mortality ranged from 11% to 33%. CONCLUSION: There was substantial variability in the critical care response in Nordic ICUs to the first wave of COVID‐19 pandemic, including usage of experimental medications. While ICU mortality was low in all countries, the observed variability warrants further attention.

With the onset of the COVID-19 pandemic, there were understandable concerns about the number of patients requiring intensive care and whether the capacity of individual health care systems would be surpassed. 1 With an increasing number of COVID-19 cases in most countries, extensive modifications of infrastructure were required in many hospitals to accommodate patients with severe infection that required critical care, including delays of elective procedures. 2 Adding to these concerns was the lack of specific therapeutic options available to shorten the course of the disease or improve the outcomes for severely ill patients. 3 Lack of personal protective equipment and vaccines, and uncertainties regarding the use of high-flow nasal oxygen therapy and non-invasive ventilation to reduce the need for invasive mechanical ventilation fuelled concerns about the risk of spreading the infection and personal safety of the intensive care unit (ICU) personnel. 4 As clinicians grappled with an unknown disease, various experimental treatment modalities such as antiretroviral medications [5] [6] [7] and immunomodulatory therapy 8 were introduced in some hospitals, bypassing general principles of good clinical practice and evidence-based medicine. In addition, more traditional methods to manage severe ARDS such as prone positioning, 9 usage of diuretics 10, 11 and ECMO 12 were utilized in the management of the most critically ill patients.

At the same time, initial reports from Northern Italy and China reported a high burden of ICU care as well as poor outcomes for those patients that required critical care, with over 5% of all confirmed cases requiring ICU management 13 and short-term mortality rates between 39% and 62%. [14] [15] [16] It is possible that these early outcomes were related to the number of patients exceeding surge capacity.

In the Nordic countries, epidemiology of COVID-19 as well as public health policies have differed substantially. The public health response in each country ranged from lockdown-policies including border closures and widespread testing, to ostensibly more permissive approaches. 17 Given the demographic similarities of the populations in the Nordic countries and the differences in the overall structure and response to COVID-19 in each country, understanding the variability in ICU surge response as well as the epidemiology and outcomes of patients admitted to ICUs is of interest.

To investigate this, a working group of researchers working on national ICU registries in the Nordic countries was formed, with the overall goal of creating a Nordic network for epidemiological research of ICU patients with COVID-19. In this first publication, we sought to describe the national response, surge response and ICU outcomes of patients admitted to Nordic ICUs in the first wave of COVID-19, to shed light on similarities and differences between the countries. Our hope is that this will aid in understanding this pandemic and improve the preparation for future pandemics.

Results: Most countries more than doubled their ICU capacity during the pandemic. For patients positive for SARS-CoV-2, the ratio of requiring ICU admission for COVID-19 varied substantially (1.6%-6.7%). Apart from age (proportion of patients aged 65 years or over between 29% and 62%), baseline characteristics, chronic comorbidity burden and acute presentations of COVID-19 disease were similar among the five countries. While utilization of invasive mechanical ventilation was high (59%-85%) in all countries, the proportion of patients receiving renal replacement therapy (7%-26%) and various experimental therapies for COVID-19 disease varied substantially (e.g. use of hydroxychloroquine 0%-85%). Crude ICU mortality ranged from 11% to 33%.

There was substantial variability in the critical care response in Nordic ICUs to the first wave of COVID-19 pandemic, including usage of experimental medications. While ICU mortality was low in all countries, the observed variability warrants further attention.

In this report, Nordic country ICU responses to the surge in patient with the COVID-19 pandemic is described, including strategies to adapt ICU capacities as need changed.

Contrasts are presented between the different Nordic country results.

Given that data collection was either through pre-existing registries in some countries, or was already largely collected, it was decided that each country would provide pre-approved summary statistics of their cohort, and a description of national surge response. A consensus on variables describing surge response and clinical data was reached via email communication between all researchers prior to any data entry and converted into Tables 1-5. An individual from each country was responsible for answering a questionnaire regarding surge response and filling in clinical data for patients admitted to the ICU. The outcomes of interest were the incidence of ICU admission, use of various ICU treatment modalities (medications, mode of respiratory and other organ support) and ICU mortality. It was decided that each country would at minimum describe all adult patients with COVID-19 admitted within 2 months following ICU admission of the first patient with COVID-19. Thus, this study presents descriptive summary statistics using prospectively and retrospectively collected data, and individual databases were not merged for data protection reasons. The details of individual datasets are described below.

Details of the data collection and outcomes in Denmark have been published previously. 18 Ethics approval for the study was not required, but access to data was granted by the Danish Patient Safety Authority (ref. 

The data from Finland have not been previously published. Ethics approval was not required due to the registry-based design.

Approval for obtaining and using registry data in summary form for purposes of this study was obtained from the Finnish Institute 

Details of the data collection and outcomes from Iceland have been published previously. 19 Institutional Review Board (IRB) approval with a waiver for informed consent was granted by the National Bioethics Committee (VSN-20-071). The data were prospectively registered in a customized database by two clinicians. The data included information on all patients with a SARS-CoV-2 infection confirmed with real-time polymerase chain reaction (qPCR) and admitted for hypoxic respiratory failure to the ICUs at Landspitali University Hospital and Akureyri Regional Hospital, the only two hospitals providing intensive care in Iceland.

Details of the data collection and outcomes from Norway have been published previously. 20 IRB approval with a waiver for informed consent was granted by the South-East Norway Regional Committee for Medical and Health Research Ethics (reference no. 135310). The data were collected from a pre-existing registry, the Norwegian Intensive Care and Pandemic Registry (NIPaR), that was modified during the pandemic to include additional comorbidities as well as type and duration of respiratory support. The data included patients admitted to ICUs in Norway with a laboratory-confirmed COVID-19 diagnosis during the study period.

Details of the data collection and outcomes from Sweden have been published previously. 21 IRB approval with a waiver for informed consent was granted by the Swedish Ethical Review Authority (no. 2020-01884 and 2020-02498). The data were collected from a preexisting registry, the Swedish Intensive Care Registry that routinely and prospectively collects data from all ICUs in Sweden. The data included all patients admitted to ICU with a positive test for SARS-CoV-2 and the ICD10 diagnosis code U07.1.

The frequencies of cases per day per country were obtained from Our World in Data. 22 Because data collection differed among participating countries, this work provides a description of a minimal set of data from each country that did not require merging of data sets. Where appropriate, data are presented normalized to the population (per million people), and exact 95% confidence intervals (Clopper-Pearson exact method). All statistics and image processing were performed in R, Version 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria), using RStudio, Version 1.1.423 (RStudio, Boston, MA).

All participating countries reported data from the beginning of March 2020 until the beginning of May (Table 1 ). Figure 1 shows a comparison of new cases and number of new ICU admissions per one million people. During this period both the highest incidence of cases, highest number of new cases and total number of cases per capita was in Iceland, and the lowest number of new cases and total number of cases per capita was in Finland (Figure 1 ; Table 1 ). There was a high variability in case fatality rate (CFR, deaths per individual positive for SARS-CoV-2 infection by qPCR); the highest CFR was in Sweden (14.4%) and the lowest CFR was in Iceland (0.6%; Table 1 ).

Three countries had available estimates of the total number of infections based on antibody screening following the first wave, and this revealed that number of infections was 2-5 times higher than cases diagnosed via qPCR (Table 1 ).

A summary of public health measures to control the pandemic is shown in Table 2 . All countries imposed widespread restrictions on visits to hospitals and nursing homes as well as the overall mobility and social contact, including limitations off the number of people allowed to convene ( Table 2 ). All countries except Sweden additionally closed primary and secondary schools and restricted non-essential services substantially.

An overview of the ICU capacity prior to and during the first wave is shown in Table 3 . Prior to the onset of the pandemic the lowest TA B L E 1 Population characteristics and overall outcomes in Nordic countries during the first wave of COVID-19 (Table 3 ). In general, there were centralized registries to track available ICU beds as well as the availability of ICU staff, equipment and medications as well as a system on a regional level to share these resources between ICUs (Table 3) . Inventory on ICU beds Regional Regional National Regional National

Inventory on ICU staff Regional Regional Regional Regional Regional

Inventory on ICU equipment Regional National Regional Regional Regional

Inventory on essential medications National National Regional National Regional

Distribution of ICU staff Regional Regional Regional Regional Regional

Distribution of ICU equipment Regional Regional Regional Regional Regional Distribution on personal protective equipment Regional National National Regional Regional

Distribution of essential medications National Regional Regional National Regional

Overview of ICU capacity prior to and during the first wave of COVID-19 pandemic and overview of national responses Table 4 shows the characteristics of COVID-19-patients admitted to admitted at day 9 after symptom onset and 1-2 days after admission to the hospital, with no major differences noted between countries.

The median duration of days spent in the ICU ranged from 10 (Iceland) to 14 (Norway) ( Table 5 ). Invasive mechanical ventilation was utilized in 59% (Iceland) to 85% (Norway) of patients admitted to the ICU with COVID-19, most commonly for 10-13 days. Prone positioning was used in more than a third of all cases in the countries with available data but the use of extracorporeal membrane oxygenation (ECMO) was uncommon (Table 5 ). Acute kidney injury was common (19%-47%), but the number of patients that received renal replacement therapy varied substantially between countries (7%-33%).

Overall ICU mortality ranged from 11% (Iceland) to 33%

(Denmark) and did not rise substantially the following discharge from the ICU (Table 5 ).

Here we describe substantial variability in the ICU surge response, characteristics and outcomes of patients admitted to Nordic ICUs during the first wave of the COVID-19 pandemic.

Public health responses varied somewhat between countries.

In general, all countries experienced substantial restriction on social activities, although there were fewer mandatory restrictions in Sweden compared to the other countries. 17 There was also likely a difference between the countries in the availability of qPCR-testing during the first wave of COVID-19. This is important to consider when interpreting the descriptive data in this report. For example, both the case fatality rate as well as the ratio of patients admitted to ICUs from those positive for SARS-CoV-2 were highest in Sweden and lowest in Iceland. Both figures reflect the availability and strategy of qPCR-testing for the disease. A limit on the capacity for testing makes it more likely that the more severely ill are tested, raising both the case fatality rate and the ratio of patients admitted to the ICU. However, since all Nordic ICU patients had confirmed SARS-CoV-2 infection, it is unlikely that outcomes within this population are affected by national population testing strategies.

Prior to the pandemic, there was a substantial variability in the number of available ICU beds between the countries. The Nordic ICU population was characterized by a moderate burden of acute disease reflecting that most patients had only a single organ failure on ICU admission. Consistent with prior studies most of the ICU patients were male and had comorbid diseases such as obesity, diabetes and cardiovascular disease. [23] [24] [25] There was a higher proportion of elderly patients in Denmark compared with the other Nordic countries, that might explain a slightly higher mortality observed there. training to support ICU staffing. 33 The primary strength of the study is the inclusion in all countries of all COVID-19 patients admitted to ICU, minimizing the risk of bias.

Most Nordic countries used established databases that allowed prospective data collection, increasing the accuracy of the registries.

The major weaknesses are our inability to pool datasets to allow di- In conclusion, we report a robust but variable ICU response towards the first wave of COVID-19 in the Nordic countries. Additionally, while ICU mortality was overall low, the outcomes of ICU patients with COVID-19 in the Nordic countries varied substantially, likely reflecting differences in surge capacity and admission criteria. Future efforts should focus on unifying variable selection and definitions, to facilitate the merging of existing ICU registries and allow direct comparison of the Nordic ICU population to optimize their care.

None.

Representatives from each country listed in the author list had full access to the data for their individual countries and are responsible for the integrity of the data and the accuracy of the data analysis for their individual countries. 

Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response

Managing ICU surge during the COVID-19 crisis: rapid guidelines

Therapeutic strategies for critically ill patients with COVID-19

Controversies in airway management of COVID-19 patients: updated information and international expert consensus recommendations

Remdesivir for the treatment of Covid-19 -Final report

Role of favipiravir in the treatment of COVID-19

Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review

Tocilizumab in patients hospitalized with covid-19 pneumonia

Prone position in intubated, mechanically ventilated patients with COVID-19: a multi-centric study of more than 1000 patients

Fluid management in ARDS: an evaluation of current practice and the association between early diuretic use and hospital mortality

Scandinavian clinical practice guideline on fluid and drug therapy in adults with acute respiratory distress syndrome

Extracorporeal Life Support O. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the chinese center for disease control and prevention

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study

Physical distancing interventions and incidence of coronavirus disease 2019: natural experiment in 149 countries

Characteristics, interventions, and longer term outcomes of COVID-19 ICU patients in Denmark-A nationwide, observational study

Nationwide incidence and outcomes of patients with coronavirus disease 2019 requiring intensive care in Iceland

Characteristics, management and survival of ICU patients with coronavirus disease-19 in Norway

National outcomes and characteristics of patients admitted to Swedish intensive care units for COVID-19: a registry-based cohort study

A cross-country database of COVID-19 testing

Gender differences in predictors of intensive care units admission among COVID-19 patients: the results of the SARS-RAS study of the Italian Society of Hypertension

Underlying conditions and risk of hospitalisation, ICU admission and mortality among those with COVID-19 in Ireland: a national surveillance study

China Medical Treatment Expert Group for C. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Mortality rates of patients with COVID-19 in the intensive care unit: a systematic review of the emerging literature

Time for tocilizumab in COVID-19?

Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

Dexamethasone in hospitalized patients with covid-19

Mortality in patients admitted to intensive care with COVID-19: an updated systematic review and meta-analysis of observational studies

Decreasing mortality rates in ICU during the COVID-19 pandemic

Scandinavian Society of A, Intensive Care M. Scandinavian clinical practice guideline on mechanical ventilation in adults with the acute respiratory distress syndrome

Training non-intensivist doctors to work with COVID-19 patients in intensive care units

A descriptive study of the surge response and outcomes of ICU patients with COVID-19 during first wave in Nordic countries